Jump Financial LLC Acquires New Holdings in Zymeworks Inc. (NYSE:ZYME)

Jump Financial LLC purchased a new position in Zymeworks Inc. (NYSE:ZYME - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 48,612 shares of the company's stock, valued at approximately $712,000. Jump Financial LLC owned about 0.07% of Zymeworks at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Sterling Capital Management LLC boosted its position in shares of Zymeworks by 781.5% during the 4th quarter. Sterling Capital Management LLC now owns 1,719 shares of the company's stock valued at $25,000 after acquiring an additional 1,524 shares in the last quarter. AlphaQuest LLC boosted its position in shares of Zymeworks by 480.2% during the 4th quarter. AlphaQuest LLC now owns 2,808 shares of the company's stock valued at $41,000 after acquiring an additional 2,324 shares in the last quarter. FMR LLC boosted its position in shares of Zymeworks by 84.2% during the 3rd quarter. FMR LLC now owns 3,336 shares of the company's stock valued at $42,000 after acquiring an additional 1,525 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Zymeworks during the 4th quarter valued at about $151,000. Finally, New York State Common Retirement Fund boosted its position in shares of Zymeworks by 42.7% during the 4th quarter. New York State Common Retirement Fund now owns 13,371 shares of the company's stock valued at $196,000 after acquiring an additional 4,000 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Zymeworks news, Director Ecor1 Capital, Llc purchased 73,953 shares of the stock in a transaction dated Wednesday, April 16th. The stock was bought at an average price of $11.16 per share, for a total transaction of $825,315.48. Following the transaction, the director now directly owns 17,773,727 shares in the company, valued at $198,354,793.32. This represents a 0.42 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders purchased 1,350,347 shares of company stock valued at $16,137,499. Insiders own 1.92% of the company's stock.

Zymeworks Stock Performance

Shares of NYSE ZYME traded up $0.31 during trading on Monday, reaching $12.88. The company had a trading volume of 494,788 shares, compared to its average volume of 616,729. Zymeworks Inc. has a 52 week low of $8.21 and a 52 week high of $17.70. The stock has a market cap of $896.15 million, a PE ratio of -8.59 and a beta of 1.18. The business's 50 day moving average price is $12.09 and its 200-day moving average price is $13.52.

Analysts Set New Price Targets

ZYME has been the topic of several recent research reports. HC Wainwright lifted their target price on shares of Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a research report on Monday, March 10th. Lifesci Capital assumed coverage on shares of Zymeworks in a report on Tuesday, March 11th. They set an "outperform" rating and a $30.00 price target for the company. Finally, Citigroup lifted their price target on shares of Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a report on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $21.00.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.